Acute myocardial infarction in Switzerland: Results from the PIMICS myocardial infarction registry;Der akute myokardinfarkt in der Schweiz: Resultate aus dem PIMICS- herzinfarkt-register

Schweizerische Medizinische Wochenschrift

Volumn 128, Issue 19, 1998, Pages 729-736

  Naegeli, B ^b   Bertel, O ^a   Urban, P ^b   Angehrn, W ^b   Siegrist, P ^b   Stauffer, J Ch ^b   Baumann, P C ^b   Jolliet, P ^b   Simeon Dubach, D ^b   Meier, B ^b   Wunderlin, R ^b  

^a Medizinische Klinik Zurich   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; FEMALE; FIBRINOLYTIC THERAPY; HEART REHABILITATION; HEART REINFARCTION; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; REGISTER; SMOKING; SWITZERLAND; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; CAPTOPRIL; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITAL MORTALITY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT ADMISSION; REGISTRIES; SWITZERLAND; TREATMENT OUTCOME;

EID: 0032499517     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. The principal investigators of the MONICA Project. WHO MONICA Project: Geographic variation in mortality from cardiovascular diseases. Baseline data on selected population characteristics and cardiovascular mortality. World health statistics quarterly 1987;40:171-84.
2. Cooper R, Stamler J, Dyer A, Garside D. The decline in mortality from coronary heart disease, U.S.A., 1968-1975. J Chron Dis 1978;31:709-20.
3. Beaglehole R. International trends in coronary heart disease. Mortality, morbidity and risk factors. Epidemiol Rev 1990; 12:1-15.
4. Rouleau JL, Talajic M, Sussex B, Potvin L, Warnica W, et al. Myocardial infarction patients in the 1990s. Their risk factors, stratification and survival in Canada: The Canadian assessment of myocardial infarction (CAMI) study. JACC 1996;27:1119-27.
5. Every NR, Spertus J, Fihn SD, Hlatky M, Martin JS, Weaver D. Length of hospital stay after acute myocardial infarction in the myocardial infarction triage and intervention (MITI) project registry. JACC 1996;28:287-93.
6. Krumholz HM, Murillo JE, Chen Y, Vaccarino V, Radford MJ, et al. Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. JAMA 1997;227:1683-8.
7. Steingart RM, Packer M, Hamm P, Coglianese ME, Gersh B, et al. Sex differences in the management of coronary artery disease. N Engl J Med 1991;325:226-30.
8. Ayanian JZ, Epstein A. Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med 1991;325:221-5.
9. Clarke KW, Gray D, Keating NA, Hampton JR. Do women with acute myocardial infarction receive the same treatment as men? Br Med J 1994;309:563-6.
10. Tunstall-Pedoe H, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the world health organization MONICA Project. Registration procedures, event rates and case fatality rates in 38 populations from 21 countries in four continents. WHO MONICA Project. Circulation 1994;90:583-612.
11. Hungerbühler P, Wietlisbach V, Rickenbach M, Vogt P. Evolution du traitement de l'infarctus du myocarde en Suisse de 1986 à 1990: les résultats d'une étude de population. Schweiz Med Wochenschr 1992;122:1919-26.
12. European Secondary Prevention Study Group. Translation of clinical trials into practice: A European population-based study of the use of thrombolysis for acute myocardial infarction. Lancet 1996;347:1203-7.
13. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, et al. ACC / AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). JACC 1996;28:1328-428.
14. Yusuf S, Anand S, Avezum Jr A, Flather M, Coutinho M. Treatment for acute myocardial infarction. Overview of randomized clinical trials. Eur Heart J 1996;17:16-29.
15. The ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM). Mortality, morbidity and infarct size at 21 days. N Engl Med 1986;314:1465-71.
16. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986/I:397-401.
17. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17'87 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988/ II: 349-60.
18. Wilcox RG, Von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988/II:525-30.
19. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-9.
20. Zijlstra F, De Boer MJ, Hoorntje JCA, Reiffers S, Reiber JHC, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;323:680-4.
21. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO II b) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621-8.
22. Beta-Blocker Heart Attack Study Group. The beta-blocker heart attack trial. JAMA 1981;246:2073-4.
23. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, et al. Effect on mortality of metoprolol in acute myocardial infarction: A double-blind randomised trial. Lancet 1981/ II:823-7.
24. Pedersen TR for the Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian multicenter study on timolol after acute myocardial infarction. N Engl J Med 1985;313:1055-8.
25. Vantrimpont P, Rouleau JL, Wun C, Ciampi A, Klein M, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the survival on ventri cular enlargement (SAVE) study. JACC 1997;29:229-36.
26. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown L, Brown EJ, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
27. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
28. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
29. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (CARE). N Engl J Med 1996;335:1001-9.
30. De Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J 1996;17:37-42.
31. Pell S, Fayerweather WE. Trends in the incidence of myocardial infarction and in associated mortality and morbidity in a large employed population 1957-1983. N Engl J Med 1985;312:1005-11.
32. Koenig W, Löwel H, Lewis M, Hörmann A. Long-term survival after myocardial infarction: Relationship with thrombolysis and discharge medication. Results of the Augsburg myocardial infarction follow-up study 1985 to 1993. Eur Heart J 1996;17:1199-206.
33. Ferrières J, Cambon JP, Ruidavets JB, Pons J. Trends in acute myocardial infarction prognosis and treatment in southwestern France between 1985 and 1990. The MONICA project Toulouse. Am J Cardiol 1995;75:1202-5.
34. Marques-Vidal P, Ferrières J, Metzger MH, Cambou JP, Filipiak B, et al. Trends in coronary heart disease morbidity and mortality and acute coronary care and case fatality from 1985-1989 in southern Germany and south-western France. Results from the MONICA projects in Augsburg and Toulouse. Eur Heart J 1997;18:816-21.
35. Wilhelmsen L, Rosengren A, Johansson S, Lappas G. Coronary heart disease attack rate, incidence and mortality 1975-1994 in Göteborg, Sweden. Eur Heart J 1997;18: 572-81.
36. Phillips BG, Yim JM, Brown EJ, Bittar N, Hoon TJ, et al. Pharmacologic profile of survivors of acute myocardial infarction at United States academic hospitals. Am Heart J 1996;131:872-8.
37. Ulvenstam G, Aberg A, Bergstrand R, Johansson S, Pennert K, et al. Long-term prognosis after myocardial infarction in men with diabetes. Diabetes 1985;34:787-92.
38. Healy B. The Yentl syndrome. N Engl J Med 1991;325: 274-6.
39. Pfister R, Gaillet R, Saner H, Pirovino M, Castelli I, Gaspoz JM. Die Vorspitalphase von Patienten mit Verdacht auf akuten Myokardinfarkt: Ergebnisse der «Oltener Herznotfallstudie». Schweiz Med Wochenschr 1997;127:479-88.